TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32379629

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied to the sternocleidomastoid, upper trapezius, and levator scapulae muscles
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham taping (ST)
Number of subjects: 30
Study: 35015847

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17160
Study: 34290337

Group type: EXPERIMENTAL
Intervention: Yoga intervention (6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Massage intervention (6 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Yoga post-massage exposure (6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Massage post-yoga exposure (6 weeks)
Number of subjects: 60
Study: 32259414

Group type: EXPERIMENTAL
Intervention: CT‐CP/OPF (Opalescence PF‐10%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PT‐HP/OGO (Opalescence GO‐10%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CT‐HP/WTC (White Class‐10%)
Number of subjects: 10
Study: 35020101

Group type: EXPERIMENTAL
Intervention: Topical nalbuphine 2 mg/ml (Group A)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Topical nalbuphine 1 mg/ml (Group B)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Topical artificial tears (Group C)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 189
Study: 35383732

Group type: EXPERIMENTAL
Intervention: SYSTANE iLux
Number of subjects: 236

Group type: COMPARATOR
Intervention: LipiFlow
Number of subjects: 236
Study: 32991652

Group type: EXPERIMENTAL
Intervention: Biphasic Calcium Phosphate (BCP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Deproteinized Bovine Bone Mineral (DBBM)
Number of subjects: 51
Study: 34933333

Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m2 on days 1 through 7 with durvalumab 1500 mg on day 1 every 4 weeks (Arm A)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Azacitidine 75 mg/m2 on days 1 through 7 without durvalumab (Arm B)
Number of subjects: 129
Study: 33729467

Group type: EXPERIMENTAL
Intervention: nCRT (neoadjuvant chemoradiotherapy) followed by minimally invasive esophagectomy (MIE)
Number of subjects: 264

Group type: COMPARATOR
Intervention: nCT (neoadjuvant chemotherapy) followed by minimally invasive esophagectomy (MIE)
Number of subjects: 264
Study: 32599257

Group type: EXPERIMENTAL
Intervention: Shared Decision Support Intervention (PtDAs including pamphlet and video)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 900
Study: 33515267

Group type: EXPERIMENTAL
Intervention: Non-nicotinic e-cigarettes with 4 mg nicotine lozenge (ENL)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine lozenge (NL)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Tobacco cigarettes (CIG)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Non-nicotinic e-cigarettes with placebo lozenges (EPL)
Number of subjects: 41
Study: 33450074

Group type: EXPERIMENTAL
Intervention: Well-Being Therapy (WBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 32769965

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Standard of care chemotherapy (SC)
Number of subjects: 265
Study: 34981580

Group type: EXPERIMENTAL
Intervention: Red Light (RL) therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Blue Light (BL) therapy
Number of subjects: 28
Study: 34476756

Group type: EXPERIMENTAL
Intervention: Kerà K2 (medical device containing 2,4,6‐octatrienoic acid and urea)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 35121105

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin Gammanorm® via pump
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin Gammanorm® via rapid push
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subcutaneous immunoglobulin Gammanorm® via pump and rapid push
Number of subjects: 30
Study: 32143084

Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure Treadmill (LBPPT) at 100% body weight
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure Treadmill (LBPPT) at 90% body weight
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure Treadmill (LBPPT) at 80% body weight
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure Treadmill (LBPPT) at 70% body weight
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure Treadmill (LBPPT) at 60% body weight
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure Treadmill (LBPPT) at varying %BW
Number of subjects: 12
Study: 35491797

Group type: EXPERIMENTAL
Intervention: Short pulse width stimulation (30μs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional pulse width stimulation (60μs)
Number of subjects: 24
Study: 33861548

Group type: EXPERIMENTAL
Intervention: Preventive haloperidol (up to 28 days)
Number of subjects: 1495

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1495
Study: 85146433

Group type: EXPERIMENTAL
Intervention: Electrical stimulation during immobilization
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonstimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electrical stimulation to the quadriceps
Number of subjects: 15
Study: 35029142

Group type: EXPERIMENTAL
Intervention: Racial/ethnic minority mothers
Number of subjects: 343
Study: 33773207

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg) with methotrexate (7.5 mg/week)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo with methotrexate (7.5 mg/week)
Number of subjects: 120
Study: 36006437

Group type: EXPERIMENTAL
Intervention: (chemo)radiotherapy with larynx V50Gy ≥ 53%
Number of subjects: 61

Group type: COMPARATOR
Intervention: Prophylactic or reactive gastrostomy tube placement
Number of subjects: 61
Study: 33180541

Group type: EXPERIMENTAL
Intervention: Household-smoking ban
Number of subjects: 284

Group type: COMPARATOR
Intervention: Continued smoking without a ban
Number of subjects: 284
Study: 33171390

Group type: EXPERIMENTAL
Intervention: Community-based maintenance program
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 97
Study: 33389108

Group type: EXPERIMENTAL
Intervention: TAU + AE (aerobic exercise using active-play video games and traditional equipment)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TAU + AE (aerobic exercise)
Number of subjects: 33

Group type: COMPARATOR
Intervention: TAU (Treatment-As-Usual)
Number of subjects: 33
Study: 35090435

Group type: EXPERIMENTAL
Intervention: Modified Facet Joint Fusion (MFF)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Posterolateral Fusion (PLF)
Number of subjects: 77
Study: 32022483

Group type: EXPERIMENTAL
Intervention: Mometasone furoate-formoterol (MF/F) 100/10 µg
Number of subjects: 181

Group type: COMPARATOR
Intervention: Mometasone furoate (MF) 100 µg
Number of subjects: 181
Study: 35384019

Group type: EXPERIMENTAL
Intervention: Small cribriform pattern
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: Large cribriform pattern
Number of subjects: 1887
Study: 32387012

Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 906

Group type: COMPARATOR
Intervention: MPSV4
Number of subjects: 906
Study: 35451099

Group type: EXPERIMENTAL
Intervention: THC cigarette
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 14
Study: 35583988

Group type: EXPERIMENTAL
Intervention: Group logotherapy (10 weekly 2-hour sessions)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 63
Study: 33559240

Group type: EXPERIMENTAL
Intervention: Long pulsed Nd:YAG laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chemical peeling
Number of subjects: 20
Study: 33167542

Group type: EXPERIMENTAL
Intervention: High-histamine diet for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low-histamine diet for 4 weeks
Number of subjects: 21
Study: 35244059

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 165
Study: 33888577

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Tolvaptan and Placebo
Number of subjects: 1445
Study: 33225801

Group type: EXPERIMENTAL
Intervention: Goal management training (support condition)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 90
Study: 32781476

Group type: EXPERIMENTAL
Intervention: Bihemispheric transcranial direct current stimulation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 17
Study: 32777998

Group type: COMPARATOR
Intervention: L-theanine 400 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: L-theanine 100 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: L-theanine 200 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 27
Study: 34816597

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (HCL) insulin delivery 24/7
Number of subjects: 122

Group type: COMPARATOR
Intervention: Evening and night (E/N) hybrid closed-loop insulin delivery
Number of subjects: 122
Study: 34805194

Group type: EXPERIMENTAL
Intervention: Open-label placebo injections (two per day on day 1 and 2 post-surgery) along with treatment as usual (patient-controlled morphine pump)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as usual (patient-controlled morphine pump)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Open-label placebo injections
Number of subjects: 70
Study: 36342884

Group type: EXPERIMENTAL
Intervention: Outpatient NIV setup using an autotitrating NIV device and a set protocol, including home oximetry.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Inpatient NIV setup with standard fixed level NIV and titrated during an attended overnight respiratory study.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both outpatient and inpatient NIV setups.
Number of subjects: 82
Study: 32056510

Group type: EXPERIMENTAL
Intervention: 6% glucose mouth rinse
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6% NaCl mouth rinse
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water mouth rinse
Number of subjects: 10
Study: 35618537

Group type: EXPERIMENTAL
Intervention: Advanced regional analgesic techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic analgesics (paracetamol, NSAIDs, cyclooxygenase-2 inhibitors, dexamethasone, local infiltration analgesia)
Number of subjects: 0
Study: 33430935

Group type: EXPERIMENTAL
Intervention: Quality Improvement Dashboards (QID) and Targeted Client Communication (TCC) via SMS
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 138
Study: 32938572

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire assessing knowledge, attitude, and practice regarding emergency management of TDI.
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire assessing perceived knowledge level.
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Need for a training program expressed by all respondents.
Number of subjects: 330
Study: 32248707

Group type: EXPERIMENTAL
Intervention: Polynucleotide (PN) filler injection
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-crosslinked hyaluronic acid (HA) filler injection
Number of subjects: 27
Study: 33975661

Group type: EXPERIMENTAL
Intervention: Bone pâté
Number of subjects: 68

Group type: COMPARATOR
Intervention: Bioactive glass
Number of subjects: 68
Study: 32975529

Group type: EXPERIMENTAL
Intervention: Portal message promoting influenza vaccinations
Number of subjects: 19506

Group type: COMPARATOR
Intervention: Usual care for portal users
Number of subjects: 19506

Group type: EXPERIMENTAL
Intervention: Interactive voice response call
Number of subjects: 19506

Group type: COMPARATOR
Intervention: Usual care for portal nonusers
Number of subjects: 19506
Study: 36127727

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 120

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 120
Study: 32311655

Group type: EXPERIMENTAL
Intervention: m-dimensional randomized sketches approach for KCCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 36477104

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Paraffin with vacuum massage
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Paraffin alone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound and vacuum massage
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study: 34264838

Group type: EXPERIMENTAL
Intervention: General practitioner (GP) characteristics and practice characteristics in New Zealand
Number of subjects: 6146

Group type: EXPERIMENTAL
Intervention: General practitioner (GP) characteristics and practice characteristics in the Netherlands
Number of subjects: 6146
Study: 32047015

Group type: EXPERIMENTAL
Intervention: Total laparoscopic pancreaticoduodenectomy (TLPD)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Open pancreaticoduodenectomy (OPD)
Number of subjects: 656
Study: 35807110

Group type: EXPERIMENTAL
Intervention: Bilateral QLBs-LSAL with 0.375% ropivacaine (20 mL each side)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Bilateral QLBs-LSAL
Number of subjects: 94

Group type: COMPARATOR
Intervention: Bilateral TQLBs
Number of subjects: 94
Study: 35240291

Group type: EXPERIMENTAL
Intervention: Resveratrol 200 mg once daily for 24 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (cellulose capsules)
Number of subjects: 110
Study: 33057887

Group type: EXPERIMENTAL
Intervention: St. John's wort oil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Virgin olive oil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate plus benzydamine hydrochloride mouthwash
Number of subjects: 90
Study: 35867532

Group type: EXPERIMENTAL
Intervention: Adjuvant hypnotherapy plus conventional therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional therapy alone (control)
Number of subjects: 41
Study: 33881456

Group type: EXPERIMENTAL
Intervention: end-HMPo2
Number of subjects: 305

Group type: COMPARATOR
Intervention: SCS
Number of subjects: 305
Study: 32799216

Group type: COMPARATOR
Intervention: C-arm-guided PKP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Double-arm DSA-guided PKP
Number of subjects: 60
Study: 35279171

Group type: EXPERIMENTAL
Intervention: Anaemia screening and treatment (anaemia arm)
Number of subjects: 19254

Group type: EXPERIMENTAL
Intervention: MSSA decolonisation (infection arm)
Number of subjects: 19254
Study: 34792268

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 358

Group type: COMPARATOR
Intervention: EUS-B-FNA
Number of subjects: 358
Study: 34205403

Group type: EXPERIMENTAL
Intervention: Food education programme based on the stages of change model
Number of subjects: 74

Group type: COMPARATOR
Intervention: Informative sessions on basic healthy eating (Control Group)
Number of subjects: 74
Study: 33932802

Group type: EXPERIMENTAL
Intervention: Combined EN and PN with omega‐3 PUFA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combined EN and PN without omega‐3 PUFA (control group)
Number of subjects: 100
Study: 32379066

Group type: EXPERIMENTAL
Intervention: RIRS
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Micro PNL
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ultra-mini PNL
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Mini PNL
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Standard PNL
Number of subjects: 168
Study: 34376084

Group type: EXPERIMENTAL
Intervention: Nonphysical IPV items (6 items)
Number of subjects: 2412

Group type: EXPERIMENTAL
Intervention: Female sex and identifying as lesbian, gay, or bisexual
Number of subjects: 2412

Group type: COMPARATOR
Intervention: Measurement invariance assumptions and dichotomization of IPV
Number of subjects: 2412
Study: 34003138

Group type: EXPERIMENTAL
Intervention: Psychoeducational interventions through a mobile phone app and nurse-assisted online support sessions for 4 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Psychoeducational interventions through a mobile phone app
Number of subjects: 82

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 82
Study: 32673128

Group type: EXPERIMENTAL
Intervention: Partitioned-survival analysis (PartSA)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Semi-Markov multi-state model (MSM)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: PartSA
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: MSM
Number of subjects: 700
Study: 35556170

Group type: EXPERIMENTAL
Intervention: PF‐72 mixed with 0.75% ropivacaine
Number of subjects: 99

Group type: COMPARATOR
Intervention: 0.75% ropivacaine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study: 33087250

Group type: EXPERIMENTAL
Intervention: High dose oral vitamin D3 (540,000 IU)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study: 35084880

Group type: EXPERIMENTAL
Intervention: TAU plus Focused Coparenting Consultation (FCC) sessions
Number of subjects: 138

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 138
Study: 33916906

Group type: EXPERIMENTAL
Intervention: Primavera programme
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control prevention intervention
Number of subjects: 287
Study: 33745547

Group type: EXPERIMENTAL
Intervention: Tacrolimus plus rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide and glucocorticoids (Ponticelli regimen)
Number of subjects: 0
Study: 33198820

Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet with or without physical activity
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-fat diet with or without physical activity
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Baseline DNA methylation score
Number of subjects: 120
Study: 33122344

Group type: EXPERIMENTAL
Intervention: 2 × N-AVD (doxorubicin, vinblastine, dacarbazine with two concomitant nivolumab infusions per cycle)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 4 × nivolumab
Number of subjects: 59
Study: 33153707

Group type: EXPERIMENTAL
Intervention: Topical mitomycin C
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intra-lesional mitomycin C
Number of subjects: 40
Study: 34219588

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 44
Study: 33929630

Group type: EXPERIMENTAL
Intervention: Evaluation of dental radiographs by dentists
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Radiographic experience
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Age of study participants
Number of subjects: 21
Study: 35280171

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 300
Study: 32301501

Group type: EXPERIMENTAL
Intervention: GSK2982772, 60 mg twice daily (b.i.d.)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: GSK2982772, 60 mg three times daily (t.i.d.)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: GSK2982772
Number of subjects: 65
Study: 35206443

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Ketogenic Diet (VLCKD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Low Caloric Diet (LCD)
Number of subjects: 26
Study: 34320288

Group type: EXPERIMENTAL
Intervention: CMV hyperimmune globulin (100 mg/kg monthly until delivery)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: CMV hyperimmune globulin
Number of subjects: 399
Study: 34910320

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sertaconazole 2% cream
Number of subjects: 60
Study: 33048569

Group type: EXPERIMENTAL
Intervention: Parental Friendship Coaching (PFC)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Coping with ADHD through Relationships and Education (CARE)
Number of subjects: 172
Study: 34740101

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 63
Study: 32954885

Group type: EXPERIMENTAL
Intervention: Home-Based Cardiac Rehabilitation (HBCR)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Facility-Based Cardiac Rehabilitation (FBCR)
Number of subjects: 237
Study: 34024233

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 10 mg/kg infusion in 100 mL normal saline
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo (distilled water in 100 mL normal saline)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 207
Study: 33099848

Group type: EXPERIMENTAL
Intervention: IDegAsp (twice-daily single injection)
Number of subjects: 52

Group type: COMPARATOR
Intervention: IDeg + Lira (once-daily dual injection)
Number of subjects: 52
Study: 34212863

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Primary composite outcome (death, MI, stroke) after PCI
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Secondary composite outcome (death, MI, stroke, IDR) after PCI
Number of subjects: 1905
Study: 34138698

Group type: EXPERIMENTAL
Intervention: Food insecure ECE providers
Number of subjects: 216
Study: 32246743

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (bodyweight-adjusted, administered once-daily, twice-daily, or thrice-daily)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (tablet and suspension formulation)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Standard anticoagulation
Number of subjects: 335
Study: 34967053

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Canadian Occupational Performance Measure (COPM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Short-Form (SF)-36 physical health component
Number of subjects: 16